Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 2, 2016, Pages 359-366

  Hofman, Zonne L M ^a   Relan, Anurag ^b   Zeerleder, Sacha ^c   Drouet, Christian ^d   Zuraw, Bruce ^e   Hack, C Erik ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Pharming Group NV   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d UNIV GRENOBLE ALPES   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angioedema attack; complement system; contact system; efficacy; Hereditary angioedema; human C1 inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 12A; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; CYTOKINE; KALLIKREIN; KININ; BRADYKININ; BRADYKININ RECEPTOR; CARRIER PROTEIN; COMPLEMENT COMPONENT C1S INHIBITOR; PROTEIN BINDING;

ANGIONEUROTIC EDEMA; BLOOD VESSEL PERMEABILITY; ENDOTHELIUM; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; ANGIOEDEMAS, HEREDITARY; ANIMAL; GENETICS; MECHANOTRANSDUCTION; METABOLISM; PHENOTYPE;

ANGIOEDEMAS, HEREDITARY; ANIMALS; BRADYKININ; CARRIER PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; MECHANOTRANSDUCTION, CELLULAR; PHENOTYPE; PROTEIN BINDING; RECEPTORS, BRADYKININ;

EID: 84969921165     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.02.041     Document Type: Review

References (109)

1. 1 Zuraw, B.J., Hereditary angioedema. N Engl J Med 359 (2008), 1027–1036.
2. 2 Agostoni, A., Aygören-Pürsün, E., Binkley, K.E., Blanch, A., Bork, K., Bouillet, L., et al. Hereditary and acquired angioedema: problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:suppl (2004), S51–S131.
3. 3 Longhurst, H., Cicardi, M., Hereditary angio-edema. Lancet 379 (2012), 474–481.
4. 4 Bork, K., Siedlecki, K., Bosch, S., Schopf, R.E., Kreuz, W., Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 75 (2000), 349–354.
5. 5 Bork, K., Meng, G., Staubach, P., Hardt, J., Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45 (2005), 1774–1784.
6. 6 Kusuma, A., Relan, A., Knulst, A.C., Moldovan, D., Zuraw, B., Cicardi, M., et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 125 (2012), 937.e17–937.e24.
7. 7 Zuraw, B.L., Sugimoto, S., Curd, J.G., The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 78 (1986), 1115–1120.
8. 8 Gompels, M.M., Lock, R.J., Morgan, J.E., Osborne, J., Brown, A., Virgo, P.F., A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor. J Clin Pathol 55 (2002), 145–147.
9. 9 Van Doorn, M.B.A., Burggraaf, J., van Dam, T., Eerenberg, A., Levi, M., Hack, C.E., et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 116 (2005), 876–883.
10. 10 Schapira, M., Silver, L.D., Scott, C.F., Schmaier, A.H., Prograis, L.J. Jr., Curd, J.G., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308 (1983), 1050–1053.
11. 11 Cugno, M., Hack, C.E., de Boer, J.P., Eerenberg, A.J., Agostoni, A., Cicardi, M., Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 121 (1993), 38–43.
12. 12 Nussberger, J., Cugno, M., Cicardi, M., Bradykinin-mediated angioedema. N Engl J Med 347 (2002), 621–622.
13. 13 Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A., Plasma bradykinin in angio-oedema. Lancet 351 (1998), 1693–1697.
14. 14 Han, E.D., MacFarlane, R.C., Mulligan, A.N., Scafidi, J., Davis, A.E. 3rd, Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 (2002), 1057–1063.
15. 15 Cicardi, M., Banerji, A., Bracho, F., Malbrán, A., Rosenkranz, B., Riedl, M., et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363 (2010), 532–541.
16. 16 Curd, J.G., Prograis, L.J. Jr., Cochrane, C.G., Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 152 (1980), 742–747.
17. 17 Nussberger, J., Cugno, M., Cicardi, M., Agostoni, A., Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104 (1999), 1321–1322.
18. 18 Hofman, Z.L.M., Relan, A., Hack, C.E., Hereditary Angioedema attacks: local swelling at multiple sites. Clin Rev Allergy Immunol 50 (2016), 34–40.
19. 19 Prematta, M.J., Kemp, J.G., Gibbs, J.G., Mende, C., Rhoads, C., Craig, T.J., Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks. Allergy Asthma Proc 30 (2009), 506–511.
20. 20 Magerl, M., Doumoulakis, G., Kalkounou, I., Weller, K., Church, M.K., Kreuz, W., et al. Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. Clin Exp Dermatol 39 (2014), 298–303.
21. 21 Schmaier, A.H., Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol 8 (2008), 161–165.
22. 22 Colman, R.W., Schmaier, A.E., Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90 (1997), 3819–3843.
23. 23 Ratnoff, O.D., Rosenblum, J.M., Role of Hageman factor in the initiation of clotting by glass. Evidence that glass frees Hageman factor from inhibition. Am J Med 25 (1958), 160–168.
24. 24 Ogston, D., Ogston, C.M., Ratnoff, O.D., Forbes, C.D., Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest 48 (1969), 1786–1801.
25. 25 Müller, F., Mutch, N.J., Schenk, W.A., Smith, S.A., Esterl, L., Spronk, H.M., et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139 (2009), 1143–1156.
26. 26 Faxälv, L., Boknäs, N., Ström, J.O., Tengvall, P., Theodorsson, E., Ramström, S., et al. Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII. Blood 122 (2013), 3818–3824.
27. 27 Oschatz, C., Maas, C., Lecher, B., Jansen, T., Bjorkqvist, J., Tradler, T., et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34 (2011), 258–268.
28. 28 Von Brühl, M.L., Stark, K., Steinhart, A., Chandraratne, S., Konrad, I., Lorenz, M., et al. Monocytes, neutrophils and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209 (2012), 819–835.
29. 29 Sanchez, J., Elgue, G., Larsson, R., Nilsson, B., Olsson, P., Surface-adsorbed fibrinogen and fibrin may activate the contact activation system. Thromb Res 122 (2008), 257–263.
30. 30 van der Meijden, P.E., Munnix, I.C., Auger, J.M., Govers-Riemslag, J.W., Cosemans, J.M., Kuijpers, M.J., et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 114 (2009), 881–890.
31. 31 Maas, C., Govers-Riemslag, J.W., Bouma, B., Schiks, B., Hazenberg, B.P., Lokhorst, H.M., et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118 (2008), 3208–3218.
32. 32 Chung, D.W., McMullen, B.A., Davie, E.W., Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 25 (1986), 2410–2417.
33. 33 Cochrane, C.G., Revak, S.D., Wuepper, K.D., Activation of Hageman factor in solid and fluid phases: a critical role of kallikrein. J Exp Med 138 (1973), 1564–1583.
34. 34 Joseph, K., Tholanikunnel, B.G., Bygum, A., Ghebrehiwet, B., Kaplan, A.P., Factor XII- independent activation of the bradykinin-forming cascade: implications for the pathogenesis of hereditary angioedema types I and II. J Allergy Clin Immunol 132 (2013), 470–475.
35. 35 Shariat-Madar, Z., Mahdi, F., Schmaier, A.H., Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277 (2002), 17962–17969.
36. 36 Ghebrehiwet, B., Silverberg, M., Kaplan, A.P., Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153 (1981), 665–676.
37. 37 Gailani, D., Renné, T., Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 27 (2007), 2507–2513.
38. 38 Kaplan, A.P., Joseph, K., Shibayama, Y., Nakazawa, Y., Ghebrehiwet, B., Reddigari, S., et al. Bradykinin formation—plasma and tissue pathways and cellular interactions. Clin Rev Allergy Immunol 16 (1998), 403–429.
39. 39 Vanhoof, G., De Meester, I., Goossens, F., Hendriks, D., Scharpé, S., Yaron, A., Kininase activity in human platelets: cleavage of the Arg1-Pro2 bond of bradykinin by aminopeptidase P. Biochem Pharmacol 44 (1992), 479–487.
40. 40 Erdös, E.G., Kinins, the long march—a personal view. Cardiovasc Res 54 (2002), 485–491.
41. 41 Skidgel, R.A., Davis, R.M., Tan, F., Human carboxypeptidase M. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J Biol Chem 264 (1989), 2236–2241.
42. 42 Leeb-Lundberg, L.M.F., Marceau, F., Muller-Esterl, W., Pettibone, D.J., Zuraw, B.L., International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 57 (2005), 27–77.
43. 43 Marceau, F., Hess, J.F., Bachvarov, D.R., The B1 receptors for kinins. Pharmacol Rev 50 (1998), 357–386.
44. 44 Dobó, J., Major, B., Kékesi, K.A., Szabó, I., Megyeri, M., Hajela, K., et al. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS One, 6, 2011, e20036.
45. 45 Etscheid, M., Beer, N., Fink, E., Seitz, R., Johannes, D., The hyaluronan binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol Chem 383 (2002), 1633–1643.
46. 46 Pixley, R.A., Schapira, M., Colman, R.W., The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 260 (1985), 1723–1729.
47. 47 Chan, J.Y., Burrowes, C.E., Habal, F.M., Movat, H.Z., The inhibition of activated factor XII (Hageman factor) by antithrombin III: the effect of other plasma proteinase inhibitors. Biochem Biophys Res Commun 74 (1977), 150–158.
48. 48 van der Graaf, F., Koedam, J.A., Bouma, B.N., Inactivation of kallikrein in human plasma. J Clin Invest 71 (1983), 149–158.
49. 49 Schapira, M., Scott, C.F., Colman, R.W., Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69 (1982), 462–468.
50. 50 Cugno, M., Cicardi, M., Bottasso, B., Coppola, R., Paonessa, R., Mannucci, P.M., et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89 (1997), 3213–3218.
51. 51 Joseph, K., Tholanikunnel, T.E., Kaplan, A.P., Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol 104 (2010), 50–54.
52. 52 Cugno, M., Cicardi, M., Coppola, R., Agostoni, A., Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 33 (1996), 361–364.
53. 53 Berrettini, M., Lammle, B., White, T., Heeb, M.J., Schwarz, H.P., Zuraw, B., et al. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 68 (1986), 455–461.
54. 54 Lämmle, B., Zuraw, B.L., Heeb, M.J., Schwarz, H.P., Berrettini, M., Curd, J.G., et al. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb Haemost 59 (1988), 151–161.
55. 55 Suffritti, C., Zanichelli, A., Maggioni, L., Bonanni, E., Cugno, M., Cicardi, M., High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin mediated angioedema due to hereditary C1-inhibitor deficiency. Clin Exp Allergy 44 (2014), 1503–1514.
56. 56 Defendi, F., Charignon, D., Ghannam, A., Baroso, R., Csopaki, F., Allegret-Cadet, M., et al. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One, 8, 2013, e70140.
57. 57 Cichon, S., Martin, L., Hennies, H.C., Müller, F., Van Driessche, K., Karpushova, A., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79 (2006), 1098–1104.
58. 58 Dewald, G., Bork, K., Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343 (2006), 1286–1289.
59. 59 Cicardi, M., Levy, R.J., McNeil, D.L., Li, H.H., Sheffer, A.L., Campion, M., et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363 (2010), 523–531.
60. 60 Dunn, J.T., Kaplan, A.P., Formation and structure of human Hageman factor fragments. J Clin Invest 70 (1984), 627–631.
61. 61 Pathak, M., Wilmann, P., Awford, J., Li, C., Hamad, B.K., Fischer, P.M., et al. Coagulation factor XII protease domain crystal structure. J Thromb Haemost 13 (2015), 580–591.
62. 62 Kaplan, A.P., Austen, K.F., A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133 (1971), 696–712.
63. 63 Pixley, R.A., Schmaier, A., Colman, R.W., Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys 256 (1987), 490–498.
64. 64 Dors, D.M., Nuijens, J.H., Huijbregts, C.C., Hack, C.E., A novel sensitive assay for functional factor XII based on the generation of kallikrein-C1-inhibitor complexes in factor XII-deficient plasma by glass-bound factor XII. Thromb Haemost 67 (1992), 644–648.
65. 65 Schousboe, I., Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 270 (2003), 111–118.
66. 66 Ravindran, S., Grys, T.E., Welch, R.A., Schapira, M., Patston, P.A., Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost 92 (2004), 1277–1283.
67. 67 Craig, T.J., Levy, R.J., Wasserman, R.L., Bewtra, A.K., Hurewitz, D., Obtułowicz, K., et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124 (2009), 801–808.
68. 68 Zuraw, B.L., Busse, P.J., White, M., Jacobs, J., Lumry, W., Baker, J., et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363 (2010), 513–522.
69. 69 Zuraw, B., Cicardi, M., Levy, R.J., Nuijens, J.H., Relan, A., Visscher, S., et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126 (2010), 821–827.
70. 70 Hack, C.E., Relan, A., van Amersfoort, E.S., Cicardi, M., Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 67 (2012), 123–130.
71. 71 Konings, J., Cugno, M., Suffritti, C., Ten Cate, H., Cicardi, M., Govers-Riemslag, J.W., Ongoing contact activation in patients with hereditary angioedema. PLoS One, 8, 2013, e74043.
72. 72 Nuijens, J.H., Huijbregts, C.C., Eerenberg-Belmer, A.J., Abbink, J.J., Strack van Schijndel, R.J., Felt-Bersma, R.J., et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. Blood 72 (1988), 1841–1848.
73. 73 de Smet, B.J., de Boer, J.P., Agterberg, J., Rigter, G., Bleeker, W.K., Hack, C.E., Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 81 (1993), 56–61.
74. 74 Wuillemin, W.A., Bleeker, W.K., Agterberg, J., Rigter, G., ten Cate, H., Hack, C.E., Clearance of human factor XIa-inhibitor complexes in rats. Br J Haematol 93 (1996), 950–954.
75. 75 Murphey, L.J., Hachey, D.L., Oates, J.A., Morrow, J.D., Brown, N.J., Metabolism of bradykinin in vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. J Pharmacol Exp Ther 294 (2000), 263–269.
76. 76 Prechel, M.M., Orawski, A.T., Maggiora, L.L., Simmons, W.H., Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung. J Pharmacol Exp Ther 275 (1995), 1136–1142.
77. 77 Zubakova, R., Gille, A., Faussner, A., Hilgenfeldt, U., Ca2+ signalling of kinins in cells expressing rat, mouse and human B1/B2-receptor. Int Immunopharmacol 8 (2008), 276–281.
78. 78 Lumry, W.R., Li, H.H., Levy, R.J., Potter, P.C., Farkas, H., Moldovan, D., et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107 (2011), 529–537.
79. 79 Marceau, F., Sabourin, T., Houle, S., Fortin, J.P., Petitclerc, E., Molinaro, G., et al. Kinin receptors: functional aspects. Int Immunopharmacol 2 (2002), 1729–1739.
80. 80 Enquist, J., Skröder, C., Whistler, J.L., Leeb-Lundberg, F., Kinins promote B2 Receptor endocytosis and delay constitutive B1 receptor endocytosis. Mol Pharmacol 71 (2007), 494–507.
81. 81 Wolsing, D.H., Rosenbaum, J.S., Bradykinin-stimulated inositol phosphate production in NG108-15 cells is mediated by a small population of binding sites which rapidly desensitize. J Pharmacol Exp Ther 257 (1991), 621–633.
82. 82 Pan, Z.K., Zuraw, B.L., Lung, C.C., Prossnitz, E.R., Browning, D.D., Ye, R.D., Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J Clin Invest 98 (1996), 2042–2049.
83. 83 Schanstra, J.P., Bataillé, E., Marin Castaño, M.E., Barascud, Y., Hirtz, C., Pesquero, J.B., et al. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kappaB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 101 (1998), 2080–2091.
84. 84 Zhang, Y., Brovkovych, V., Brovkovych, S., Tan, F., Lee, B.S., Sharma, T., et al. Dynamic receptor-dependent activation of inducible nitric-oxide synthase by ERK-mediated phosphorylation of Ser745. J Biol Chem 282 (2007), 32453–32461.
85. 85 McLean, P.G., Ahluwalia, A., Perretti, M., Association between kinin B1 receptor and leukocyte trafficking across mouse mesenteric post-capillary venules. J Exp Med 192 (2000), 367–380.
86. 86 Brovkovych, V., Zhang, Y., Brovkovych, S., Minshall, R.D., Skidgel, R.A., A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase. J Cell Mol Med 15 (2011), 258–269.
87. 87 Regoli, D., Marceau, F., Lavigne, J., Induction of B1 receptors for the kinins in the rabbit by bacterial lipopolysaccharide. Eur J Pharmacol 71 (1981), 105–115.
88. 88 Phagoo, S.B., Poole, S., Leeb-Lundberg, L.M., Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1beta shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 56 (1999), 325–333.
89. 89 Christiansen, S.C., Eddleston, J., Woessner, K.M., Chambers, S.S., Ye, R., Pan, Z.K., et al. Up-regulation of functional kinin B1 receptors in allergic airway inflammation. J Immunol 169 (2002), 2054–2060.
90. 90 Bossi, F., Fischetti, F., Regoli, D., Durigutto, P., Frossi, B., Gobeil, F., et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 124 (2009), 1303–1310.
91. 91 Stanisavljevic, S., Ignjatovic, T., Deddish, P.A., Brovkovych, V., Zhang, K., Erdös, E.G., et al. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J Pharmacol Exp Ther 316 (2006), 1153–1158.
92. 92 Drouet, C., Désormeaux, A., Robillard, J., Ponard, D., Bouillet, L., Martin, L., et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 121 (2008), 429–433.
93. 93 Charignon, D., Ghannam, A., Defendi, F., Ponard, D., Monnier, N., López Trascasa, M., et al. Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype. Allergy 69 (2014), 1659–1665.
94. 94 Arcoleo, F., Salemi, M., La Porta, A., Selvaggio, V., Mandalà, V., Muggeo, V., et al. Upregulation of cytokines and IL-17 in patients with hereditary angioedema. Clin Chem Lab Med 52 (2014), e91–e93.
95. 95 Hofman, Z.L., Relan, A., Hack, C.E., C-reactive protein levels in hereditary angioedema. Clin Exp Immunol 177 (2014), 280–286.
96. 96 Csuka, D., Varga, L., Farkas, H., Füst, G., Strong correlation of high EBNA-1-IgG levels with edematous attacks involving upper airway mucosa in hereditary angioedema due to C1-inhibitor deficiency. Mol Immunol 49 (2012), 649–654.
97. 9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 20 (1999), 421–430.
98. 98 Siebeck, M., Cheronis, J.C., Fink, E., Kohl, J., Spies, B., Spannagl, M., et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 receptor. J Appl Physiol 77 (1994), 2675–2680.
99. 99 Barratt-Due, A., Johansen, H.T., Sokolov, A., Thorgersen, E.B., Hellerud, B.C., Reubsaet, J.L., et al. The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock 36 (2011), 517–523.
100. 100 Cayla, C., Todiras, M., Iliescu, R., Saul, V.V., Gross, V., Pilz, B., et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 21 (2007), 1689–1698.
101. 101 Merino, V.F., Todiras, M., Campos, L.A., Saul, V., Popova, E., Baltatu, O.C., et al. Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J Mol Med 86 (2008), 791–798.
102. 102 Joseph, K., Tholanikunnel, B.G., Ghebrehiwet, B., Kaplan, A.P., Interaction of high molecular weight kininogen binding proteins on endothelial cells. Thromb Haemost 91 (2004), 61–70.
103. 103 Joseph, K., Ghebrehiwet, B., Peerschke, E.I., Reid, K.B., Kaplan, A.P., Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular “heads” of C1q (gC1q-R). Proc Natl Acad Sci U S A 93 (1996), 8552–8557.
104. 104 Zhang, X., Tan, F., Brovkovych, V., Zhang, Y., Skidgel, R.A., Cross-talk between carboxypeptidase M and the kinin B1 receptor mediates a new mode of G protein-coupled receptor signaling. J Biol Chem 286 (2011), 18547–18561.
105. 105 Zhang, X., Tan, F., Zhang, Y., Skidgel, R.A., Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient B1 signaling from B2 agonists. J Biol Chem 283 (2008), 7994–8004.
106. 106 Zhang, X., Tan, F., Skidgel, R.A., Carboxypeptidase M is a positive allosteric modulator of the kinin B1 receptor. J Biol Chem 288 (2013), 33226–33240.
107. 107 Sangsree, S., Brovkovych, V., Minshall, R.D., Skidgel, R.A., Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol 284 (2003), 1959–1968.
108. 108 Schremmer-Danninger, E., Offner, A., Siebeck, M., Roscher, A.A., B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun 243 (1998), 246–252.
109. 109 Charignon, D., Späth, P., Martin, L., Drouet, C., Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother 13 (2012), 2233–2247.